New research from the University of Georgia suggests that something as simple as a cup of tea can help in the fight against COVID-19.
Apr 8, 2024
0
640
A new approach to the guidance, planning and conduct of heart bypass surgery has been successfully tested on patients for the first time in a clinical trial coordinated by a research team at University of Galway.
Apr 8, 2024
0
0
Weill Cornell Medicine scientists have developed an innovative human neuron model that robustly simulates the spread of tau protein aggregates in the brain—a process that drives cognitive decline in Alzheimer's disease ...
Apr 5, 2024
0
51
For the past several years, Washington University in St. Louis researchers have been using focused ultrasound combined with microbubbles to target an opening in the tough, protective blood-brain barrier to deliver drugs or ...
Apr 5, 2024
0
19
A combination of immunotherapy and targeted therapies show promise in managing metastatic renal cell carcinoma (RCC), the most common form of kidney cancer that makes up 90% of all cases. However, accurately predicting responses ...
Apr 5, 2024
0
59
Testing for tumor DNA in the blood can successfully identify advanced bladder cancer patients who will not relapse following surgery, new research shows.
Apr 4, 2024
0
2
The test that was developed using an existing diagnostic procedure as its basis and has the potential to be applied in clinical trials that target the Epstein Barr Virus.
Apr 4, 2024
0
0
A recent Mayo Clinic study suggests that active workstations incorporating a walking pad, bike, stepper and/or standing desk are successful strategies for reducing sedentary time and improving mental cognition at work without ...
Apr 4, 2024
0
0
Hypoxia-activated prodrugs (HAPs) have the potential to activate specifically in hypoxic tumors and eliminate tumor cells, which has brought new opportunities for safe and effective anticancer therapy. However, their therapeutic ...
Apr 3, 2024
0
0
More patients these days are taking part in cancer research, a new study finds.
Apr 3, 2024
0
0
